Pogue Mahone
The caf's Camus.
Cool. Very little to nit-pick there (other than lowish number of subjects). A well designed, well executed study. Using a different adenovirus for second dose makes a lot of sense and might explain excellent efficacy. These are arguably the most impressive results to date.It's an interim report but it's got what looks like the most useful (to outsiders) data in it.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia - The Lancet
And the appendices:
mmc1.pdf (thelancet.com)
Also worth noting they’ve had a freeze dried version already approved in Russia. Storage at 2-8C.